LakeShore Biopharma has received regulatory approval for a novel packaging solution for its YSJA™ rabies vaccine featuring needle-free reconstitution technology, with nationwide distribution in China beginning within weeks.
AIM Vaccine Co., Ltd. has pre-applied for marketing approval of its serum-free rabies vaccine, which showed excellent safety and immunogenicity in Phase III trials.
AIM Vaccine's iterative serum-free rabies vaccine demonstrated strong immunogenicity and safety in Phase III trials, meeting all pre-set clinical objectives.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.